Introduction
Interleukin 13 (IL13) is a cytokine that elicits both proinflammatory and anti-inflammatory immune responses [1, 2] . IL13 is structurally homologous to IL4 and contains four (A, B, C, and D) a-helices. IL13 and IL4 bind to IL13/4 receptor (IL13/4R), a heterodimeric receptor complex composed of IL13Ra1 and IL4Ra, that is expressed in many normal organs and in adenocarcinomas [3 -5] . However, IL13 binds malignant brain tumor (glioma) cells independently of IL4, which indicated the existence of another binding moiety specific for IL13 [6, 7] . Subsequently, IL13 receptor a 2 (IL13Ra2) was cloned [8] and this monomeric protein exhibits affinity for IL13, but not IL4. Our studies revealed that malignant gliomas overexpress this restricted receptor for IL13 and that IL13Ra2 is the molecular entity responsible for the binding of IL13 to glioma tumors [9 -13] .
We have been analyzing the structure -function relationship for the purpose of redirecting IL13 from its normal tissue receptor, IL13/4R, to the tumor-associated receptor, IL13Ra2 [14] . We demonstrated that residues in a-helix A (Pro-7 to Gln-23), a-helix C (Ala-60 to Cys-72), and a-helix D (Lys-90 to Glu-110) take part in the interaction with both IL13Ra2 and IL13/ 4R ( Figure 1 ) [15 -17] . For example, we discovered glutamic acid at position 13 (a-helix A) to be a ''hot spot'' for IL13 interaction with IL13/4R, and it contributes to site I of the binding regions in IL13 [17] . Thus, IL13 with mutation of the glutamic acid at position 13 to lysine (IL13.E13K) does not bind nor activate IL13/4R, but it retains avidity toward the glioma-restricted IL13Ra2 [16] . Similarly, IL13.R66D and IL13.S69D mutants (a-helix C) binding to the IL13/4R is altered without a loss of its affinity toward the glioma-restricted receptor [17] .
Hypothetically, site II of the IL13Ra2 binding region in IL13 was considered to be located in another helix, a-helix D, at the C-terminal end of the cytokine [15] . Of interest, the first IL13 mutant in D helix, IL13.R109D, showed an impaired interaction with glioma cells [17] . This experimental result strongly supported the notion of a-helix D belonging to the receptor binding site II of IL13. However, no derivatives of IL13 were known with selectively enhanced recognition of the IL13Ra2.
More recently, we performed alanine scanning of the entire a-helix D segment of human IL13 in order to systematically delineate the residues that take part in the binding to IL13Ra2 (Figure 1 ) [18] . Thus, we found that residues 105, 106, and 109 in the a-helix D region of IL13 form the interacting triad toward the glioma-restricted receptor, a new receptor binding ''hot spot'' in IL13 [18] . Moreover, we noted that these three residues are the only hydrophilic ones located in the amphipathic middle region of a-helix D, comprising the motif LLLHLKKLFR (hydrophilic residues are in bold) (Figure 1 ) [18] . In our present investigation, we have substituted amino acids at positions 105, 106, and 109 in the a-helix D region with amino acids other than alanine, based on the charge, chain length, and bulkiness of the residues, and analyzed their functional properties. In the course of this investigation, we have identified the first mutants of IL13 of higher avidity toward the IL13Ra2 when compared with wild-type cytokine.
Materials and Methods

Materials
The mutagenesis primers were synthesized in-house in Macromolecular Core Laboratory, Pennsylvania State University College of Medicine (Hershey, PA). Fast protein liquid chromatography (FPLC), columns and media, and unique site elimination mutagenesis kit were obtained from Amersham Pharmacia Biotech (Piscataway, NJ). Glioblastoma multiforme (GBM) (a grade IV astrocytoma) U-251 MG cell line was from American Type Culture Collection (ATCC; Rockville, MD). G-26 mouse glioma cells were transfected with IL13Ra2 receptors to obtain G-26-IL13Ra2 + cells [11] .
The TF-1 cell line was obtained from the ATCC. Tissue culture equipment were from Corning Glass (Corning, NY). I labeling was purchased from Pierce.
Methods
Expression, purification, and structural characterization of IL13 a-helix D mutants The plasmid was constructed with T7 promoters and isopropyl-1thio-h-D-galactopyranoside (IPTG) -inducible T7 RNA polymerase gene in IPTG-inducible form [16] . The primers for mutagenesis were designed using Vector NTI suite software and mutagenesis was performed by site-directed mutagenesis using a selection primer and a mutagenic primer. A selection primer 5V-TGAG-GATCCGAGCTCTAATCTAGAGGCTG CTAAC-3V was used to introduce XbaI site in pIL13-CLS plasmid in place of EcoRI site to carry out restriction selection digestion and transformation in the process of mutagenesis.
The Escherichia coli cells transformed with plasmids were allowed to grow until A 600 reached 2.0. Then the cells were induced with 250 mM final concentration of IPTG and incubated at 37jC for 2 hours in a 1-l flask with shaking. The inclusion body pellets were isolated and solubilized in 7 M guanidine HCl and renatured in the presence of L-arginine and oxidized glutathione, as described previously [17] . The renatured proteins were dialyzed against 10 mM sodium acetate buffer, pH 5.2, and purified on ion exchange columns SP Sepharose and Mono S (Amersham Pharmacia Biotech) columns.
SDS-PAGE and Western blot analyses
The purity and molecular weight of the D-helix mutants were verified by SDS-PAGE under nonreducing conditions. The procedure for SDS-PAGE has been described elsewhere [18] . All SDS polyacrylamide gels were 15%. After electrophoresis, the gel was stained in Coomassie blue. For Western blot analysis, the proteins were transferred to PVDF membrane using standard electroblotting procedures. The PVDF membrane was blocked with 5% nonfat dry milk in phosphate-buffered saline (PBS) with 0.05% Tween 20 at 4jC overnight. Then the membrane was incubated at room temperature in 5% milk containing the polyclonal goat anti -human IL13 antibody (1:1000 dilution) for 45 minutes. The membrane was washed three times with 0.05% Tween 20/PBS followed by 45-minute incubation in 5% milk containing secondary antibody, antigoat IgG conjugated to horseradish peroxidase. Subsequently, the membrane was washed three times with 0.05% Tween 20/PBS. The proteins were detected on the film by enhanced chemiluminescence (ECL) detection system (Pierce).
Circular dichroism (CD) spectrum analysis The protein samples used for CD spectrum analyses were dissolved in PBS (0.1 mg/ml). All the analyses were performed in a quartz cuvette with a path length of 1 mm using a Jasco (Eden Prairie, MN) J-710 spectropolarimeter. The spectra were recorded in the wavelength region of 200 to 260 nm, and the spectra were subtracted from the blank PBS spectrum.
Cytotoxicity neutralization assay using constant concentrations of IL13 mutants The cytotoxicity neutralization experiment was performed as described elsewhere [17] . IL13-PE38QQR is a cytotoxin and fusion protein composed of IL13 and Pseudomonas exotoxin (PE38QQR), which was used in the assay [5] . Briefly, 1 Â were plated in 96-well culture plates and incubated at 37jC, 5% CO 2 , and 90% humidity for 24 hours. The receptor sites on the cells were blocked with IL13 or its mutants, at a final protein concentration of 1 mg/ml, for 1 hour at 37jC in the incubator. Subsequently, the cytotoxin, IL13-PE38QQR, was added at increasing concentrations (0.01 -100 ng/ml final concentration) and the plates were incubated for 48 hours. The proliferated cells in each well were determined by colorimetric MTS/PMS method, as described [18] . All the experiments were performed in duplicates.
Cytotoxicity neutralization assay using constant concentrations of IL13-based cytotoxin The assay was performed as described above except that the inhibitor's (IL13 or its mutants) concentrations varied, whereas the concentration of cytotoxin was constant. The U-251 MG or G-26-IL13Ra2 + cells plated in 96-well plates were blocked with IL13 or its mutants (0.1 -1000 ng/ml final concentration) for 1 hour at 37jC. Then, IL13-PE38QQR at a concentration of 10 ng/ml was added and incubated at 37jC for 48 hours. Following incubation, the proliferated cells in each well were determined by colorimetric MTS/PMS method.
TF-1 cell proliferation (IL13/4R stimulation) assay
The proliferation assay was carried out in 96-well culture plates and the cells were allowed to grow in the presence of different concentrations of IL13 and its mutants, and incubated at 37jC, 5% CO 2 , and 90% humidity for 72 hours. The rate of proliferation was determined by colorimetric MTS/PMS cell proliferation assay and the absorbency of each well at 490 nm was recorded on a microplate reader. Cells treated with high concentrations of cyclohexamide served as background for the assay. The experiment was performed in duplicate. for 3 hours. Then the cells were harvested in a cell harvester, followed by the radioactivity measurement in a g-counter.
IL13Ra2 receptor binding analyses
The second set of binding assays was performed in the form of equilibrium competition assays using increasing concentrations of the unlabeled IL13 or its mutants (10 pM -10 nM) in the presence of a constant concentration of the labeled [ 125 I]IL13 (100 pM). For this assay, 0.2 Â 10 6 cells (G-26-IL13Ra2 + cells) were used. They were incubated at 4jC for 3 hours, followed by harvesting in a cell harvester and counting in a g-counter. Analyses of the binding assays were carried out using the computer program, Graphpad Prism (San Diego, CA). The K i values were calculated by the program Prism using the equation of Cheng and Prusoff [19] :
The K i value represents an affinity of the radioligand ([ 125 I]IL13) toward the receptor in the presence of competitive inhibitor ligands. Each experiment was performed in duplicate.
Results and Discussion
Site-Directed Mutagenesis of a-Helix D Residues of Human IL13 a-Helix D of the IL13 molecule is composed of 24 amino acid residues. Based on the results of alanine scanning mutagenesis [18] , we have selected residues, which appeared to be of greatest importance for the binding of IL13 to IL13Ra2, and mutated them to charged or neutral residues. A series of single-site mutagenic primers was constructed (Table 1 ). In particular, residues Lys-105, Lys-106, and Arg-109 were substituted for amino acids of varying charge, chain length, and bulkiness of functional groups. The residues Ala-94 and Gln-95 were mutated as well because they had displayed a partial impairment in their ability to interact with IL13Ra2. We also changed hydroxyproline at position 103 to proline in an intended helix-destabilizing manner.
Expression and Purification of Recombinant Interleukins
All the expressed proteins in E. coli were localized to the inclusion bodies and, on average, the yield of all the purified proteins was found to be 0.5 to 1 mg/liter culture, except for IL13.K105L, IL13.H103P, and IL13.R109L. IL13 mutant proteins were pure and homogeneous with an approximate molecular mass of f13 kDa after the purification on SP Sepharose fast flow and Mono S columns (Figure 2A ). All the mutant proteins were immunoreactive using an anti -IL13 antibody and Figure 2B demonstrates the Western blot of several representative mutants.
CD Spectrum Analysis of a-Helix D Mutants of IL13
The CD spectra of the studied D-helix mutant proteins of IL13 were analyzed according to the reported procedure [18] . All the mutant proteins were folded properly into a-helical enriched structure, as all of them exhibited two spectral minima at 208 and 222 nm, a characteristic property of helical proteins (not shown).
IL13 Mutants Neutralization of Cell Killing by a IL13-Based Cytotoxin
The cytotoxicity neutralization assay was carried out in U-251 MG and G-26-IL13Ra2 + cells, which express IL13Ra2
either naturally or as a transgene, respectively (Figure 3) . These experiments were performed in order to reveal the . This is in line with our earlier study where the replacement of lysine at position 105 with alanine resulted in total loss of cytotoxicity neutralization efficiency of the mutant [18] . Surprisingly, substitution of lysine at position 105 to arginine (IL13.K105R) resulted in a mutant with at least, similar to wild-type IL13, cytotoxicity neutralization efficiency in the two studied cancer cell lines ( Figure 3, A and B) . Similar to the phenomenon observed with Lys-105, an anionic glutamic acid substitution at position 106 resulted in partial loss in cytotoxicity neutralization efficiency of IL13.K106E in U-251 MG and G-26-IL13Ra2 + cells ( Figure 3, A and B) . However, the IL13.K106R mutant was able to neutralize IL13-PE38QQR cytotoxicity and behaved similar to wild-type IL13 ( Figure 3, A and B) . Furthermore, substitution of arginine at position 109 in a-helix D to other amino acids, such as leucine and aspartic acid, also resulted in mutants with altered cytotoxicity neutralization capacities by displaying a poor neutralization efficiency of IL13-PE38QQR cytotoxicity in glioma cells ( Figure 3, A and B) . Again, substitution of similarly charged lysine in the place of arginine (IL13.R109K) resulted in an unaltered neutralization efficiency of the mutant when compared with an intact cytokine ( Figure 3, A and B) . Thus, the results obtained with substitution mutants at positions 105, 106, and 109 are consistent with the results of the alanine scanning mutagenesis studies [18] . Of great interest, we have found evidence that substitution mutants at position 105 and 109, such as IL13.K105R and IL13.R109K, resulted in IL13 of high avidity toward the tumor-associated receptor mutants.
We also made a substitution of alanine at position 94 to arginine. This substitution did not result in any prominent loss of cytotoxicity neutralization potential of the mutant in either U-251 MG cells (Figure 3A ) or in G-26-IL13Ra2 + cells ( Figure 3B ). However, mutation of glutamine at position 95 to arginine resulted in impaired cytotoxicity neutralization efficiency when compared with wild-type IL13 (Figure 3, A  and B) . Furthermore, the mutant IL13.H103P did not lose all cytotoxicity neutralization efficiency when compared to wildtype IL13, which implies that proline at position 103 may not completely disrupt the helical orientation of a-helix D ( Figure  3, A and B) .
Titered Cytotoxicity Neutralization Experiment
Next, we performed cytotoxicity neutralization assay in a reversed scenario: a constant concentration of the cytotoxin was used instead of serial dilutions (10 ng/ml), and serial dilutions of IL13 mutants were used instead of constant concentrations (0.1 -1000 ng/ml); IL13-PE38QQR cytotoxin efficiently kills malignant glioma cells at 10 ng/ml. The cytotoxicity neutralization potential of the wild-type IL13 and its mutants at variable concentrations of the ligand and at a constant concentration of the cytotoxin is demonstrated in Figure 4 .
In this titered cytotoxicity neutralization experiment, the highest neutralization efficiency was consistently observed for IL13K105R. IL13.K105R neutralized the cytotoxicity by 99% at 100 ng/ml concentration when compared with the mutant's blocking efficiency at 1000 ng/ml. The wild-type IL13 and the IL13.K106R and IL13.R109K mutants exhibited 86.5%, 86.7%, and 80.7% cytotoxicity neutralization efficiency, respectively. We then determined effective neutralization concentration (ENC) as a minimum concentration of the cytokine that would bring about 50% of cytotoxicity neutralization. ENC was found to be lower for IL13.K105R (10 ng/ml) than that for the wild-type IL13 (50 ng/ml) ( Figure 4 ). In addition, IL13.R109K had a strong tendency to neutralize the cytotoxin at lower concentrations that wild-type IL13, but less so than IL13.K105R. The least competitive to neutralize the cytotoxicity of IL13-PE38QQR was IL13.R109K; however, it was still neutralizing better than wild-type IL13 (Figure 4 ). This experiment underlined the better cytotoxicity neutralizing potential of IL13.K105R, IL13.R109K, and IL13.K106R, compared to that seen with wild-type IL13. Thus, these mutants exhibited an enhanced ability to compete for the receptor sites used functionally by the IL13-based cytotoxin.
IL13Ra2 Receptor Binding Studies of IL13 D-Helix Mutants
The Table 2 ). The K i values of competitive ligands, namely IL13.K105R, IL13.K106R, and IL13.R109K, were calculated ( Table 2 ). The results indicate that IL13.K105R and IL13.R109K are potent competitive ligands for the iodo -IL13 binding to IL13Ra2, with the K i values being 0.025 and 0.068 nM, respectively. However, Wild-type IL13 and neutralizing mutants were serially diluted (0.01 -1000 ng/ml) whereas IL13-PE38QQR concentration was constant (10 ng/ml). The experiments were performed using colorimetric cell MTS/PMS proliferation assay. Vertical bars correspond to standard deviation. Higher percentage of cells was protected against IL13-PE38QQR cytotoxicity when, for example, the IL13.K105R mutant was used rather than the wild-type IL13. [20] . Hence, TF-1 cell proliferation assay directly reflects an ability of the mutants to bind effectively and activate IL13/4R. The TF-1 cell proliferation ability of a-helix D mutants is demonstrated in Figure 6 . The mutant proteins like IL13.K105D, IL13.K105L, IL13.K105E, IL13.K106E, and IL13.R109D lacked proliferative activity on TF-1 cells. However, mutants like IL13.K105R, IL13.K106R, and IL13.R109D proliferated TF-1 cells similarly to wild-type IL13. Noteworthy, IL13.K105R, IL13.K106R, and IL13.R109D did not appear to a have clear-cut superagonistic activities toward IL13/4R.
Triad of Residues in IL13 That Takes Part in the Interaction with IL13Ra2
Residues Lys-105, Lys-106, and Arg-109 in IL13 are solvent-accessible and are the most likely residues to be involved in receptor binding interactions [18] . Furthermore, these three residues are in close spatial proximity in the three-dimensional structure of IL13. Our results demonstrate that residue Lys-105 in the a-helix D region in IL13 is a receptor contact site as its substitution to uncharged or negatively charged residues (e.g., leucine, alanine, glutamic acid, aspartic acid, etc.) resulted in overall loss in their binding to the glioma-restricted receptor. However, to our surprise, the substitution of this amino acid with another positively charged amino acid, arginine, resulted in a mutant, which binds IL13Ra2 more competitively when compared with wild-type IL13. Thus, substitutions with glutamic acid, leucine, and aspartic acid likely distort the recognition site, resulting in an impaired binding affinity for the receptor, whereas substitution with positively charged arginine results in an enhanced avidity. It is plausible that the contact sites in the IL13Ra2 protein involve negatively charged residue(s) or neutral residue(s). It is also noteworthy that the large residues, such as arginine, contribute to the higher side-chain flexibility of the ligand -receptor interface [21] . Figure 7 indicates the orientation of receptor binding residues in a-helix A, B, and C in IL13. Our previous studies demonstrated that IL13.E13K in A-helix and IL13.R66D and IL13.S69D in C-helix retained an ability to interact with IL13Ra2, but not with the shared IL13/4R, which is composed of IL4Ra and IL13Ra1. Thus, we conclude that the residues Glu-13, Arg-66, and Ser-69 are the contact residues with IL4Ra, and Lys-105 and Arg-109 in the C-terminal region of IL13 are the contact residues with IL13Ra2 ( Figure 7) . The IL4Ra receptor and the IL13Ra2 interacting residues lie, respectively, at receptor binding site I (yellow) and receptor binding site II (green) in the IL13 molecule, as shown in Figure 7 .
In order to further visualize the function of Lys-105 and Arg-109 residues in IL13 binding to IL13Ra2, we modeled the structural side-chain changes at position 105 upon substitution with various amino acids using Swiss-PDB molecular viewer and the coordinates available from the solution structure for IL13, as presented in Figure 8 [22, 23] . The proximity between the side chain -NH 2 group (residue 105) and -C (NH 2 )NH -group (residue 109) and their orientation is shown in Figure 8 . It is plausible that such orientation favors the residues to anchor the receptor site coordinately and that this is achieved more optimally in the IL13.K105R version of the cytokine ( Figure 8B ). All the other mutants, namely IL13.K105E, IL13.K105D, IL13.K105A, and IL13.K105L did not have the extended side chain at position 105 in order to provide hypothetically required optimal space for the interaction with the receptor (e.g., IL13.K105E in Figure 8C ). Thus, we propose that IL13 interacts with IL13Ra2 coordinately through positions 105 and 109, providing an ambient anchoring toward IL13Ra2.
Conclusion
The a-helix D mutants of IL13, IL13.K105R, and IL13.R109K were found to bind IL13Ra2 better than the native protein.
The most plausible explanation for this phenomenon is the orientation and alignment of positions 105 and 109 in the a-helix D region toward the receptor engagement. Thus, we identified mutants of IL13 having desired characteristics for future development of tumor targeting molecules while sparing normal organs [15] . Previously, we presented evidence for IL13Ra2 being a unique molecular target in cancer [11] . Several therapeutic approaches that target this receptor, including vaccines [24] , gene therapy [25] , passive immunotherapy represented by retargeted cytotoxic T cells [26] , and new IL13-based cytotoxins [12, 27] , are being developed preclinically and clinically. New mutant proteins of IL13 will facilitate achieving the goal of developing agents of specific targeting properties to the tumor-associated receptor, IL13Ra2.
